AU2013329199A1 - Combinations - Google Patents
Combinations Download PDFInfo
- Publication number
- AU2013329199A1 AU2013329199A1 AU2013329199A AU2013329199A AU2013329199A1 AU 2013329199 A1 AU2013329199 A1 AU 2013329199A1 AU 2013329199 A AU2013329199 A AU 2013329199A AU 2013329199 A AU2013329199 A AU 2013329199A AU 2013329199 A1 AU2013329199 A1 AU 2013329199A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- administered
- cancer
- amino
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261712869P | 2012-10-12 | 2012-10-12 | |
| US61/712,869 | 2012-10-12 | ||
| US201361833561P | 2013-06-11 | 2013-06-11 | |
| US61/833,561 | 2013-06-11 | ||
| PCT/US2013/064260 WO2014059095A1 (en) | 2012-10-12 | 2013-10-10 | Combinations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2013329199A1 true AU2013329199A1 (en) | 2015-04-16 |
Family
ID=50477878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013329199A Abandoned AU2013329199A1 (en) | 2012-10-12 | 2013-10-10 | Combinations |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20160263116A1 (enExample) |
| EP (1) | EP2906215A4 (enExample) |
| JP (1) | JP2015533165A (enExample) |
| KR (1) | KR20150067323A (enExample) |
| CN (1) | CN104755079A (enExample) |
| AU (1) | AU2013329199A1 (enExample) |
| BR (1) | BR112015008155A2 (enExample) |
| CA (1) | CA2888094A1 (enExample) |
| IN (1) | IN2015DN02667A (enExample) |
| RU (1) | RU2015117483A (enExample) |
| WO (1) | WO2014059095A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2945387T3 (es) | 2014-02-07 | 2023-06-30 | Verastem Inc | Procedimientos y composiciones para tratar el crecimiento celular anormal |
| GB201510628D0 (en) * | 2015-06-17 | 2015-07-29 | Glaxosmithkline Ip No 2 Ltd | Novel use |
| WO2021047783A1 (en) | 2019-09-13 | 2021-03-18 | The Institute Of Cancer Research: Royal Cancer Hospital | Vs-6063 in combination with ch5126766 for the treatment of cancer |
| MX2022012472A (es) * | 2020-04-08 | 2022-12-15 | Aptabio Therapeutics Inc | Agente para el tratamiento de lesion renal aguda inducida por medio de contraste. |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010322105B2 (en) * | 2009-11-17 | 2014-05-08 | Novartis Ag | Combination |
| WO2012045194A1 (en) * | 2010-10-09 | 2012-04-12 | Abbott Laboratories | Benzodiazepinones as fak inhibitors for treatment of cancer |
| WO2012103276A1 (en) * | 2011-01-26 | 2012-08-02 | Glaxo Wellcome Manufacturing Pte Ltd | Combinations |
-
2013
- 2013-10-10 RU RU2015117483A patent/RU2015117483A/ru not_active Application Discontinuation
- 2013-10-10 JP JP2015536880A patent/JP2015533165A/ja active Pending
- 2013-10-10 KR KR1020157011950A patent/KR20150067323A/ko not_active Withdrawn
- 2013-10-10 IN IN2667DEN2015 patent/IN2015DN02667A/en unknown
- 2013-10-10 AU AU2013329199A patent/AU2013329199A1/en not_active Abandoned
- 2013-10-10 CA CA2888094A patent/CA2888094A1/en not_active Abandoned
- 2013-10-10 CN CN201380055435.XA patent/CN104755079A/zh active Pending
- 2013-10-10 WO PCT/US2013/064260 patent/WO2014059095A1/en not_active Ceased
- 2013-10-10 EP EP13845429.3A patent/EP2906215A4/en not_active Withdrawn
- 2013-10-10 BR BR112015008155A patent/BR112015008155A2/pt not_active IP Right Cessation
- 2013-10-10 US US14/680,416 patent/US20160263116A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2015117483A (ru) | 2016-12-10 |
| EP2906215A4 (en) | 2016-05-18 |
| IN2015DN02667A (enExample) | 2015-09-04 |
| KR20150067323A (ko) | 2015-06-17 |
| CA2888094A1 (en) | 2014-04-17 |
| EP2906215A1 (en) | 2015-08-19 |
| CN104755079A (zh) | 2015-07-01 |
| BR112015008155A2 (pt) | 2017-07-04 |
| WO2014059095A1 (en) | 2014-04-17 |
| JP2015533165A (ja) | 2015-11-19 |
| US20160263116A1 (en) | 2016-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012330885B2 (en) | Oral immediate release formulations for substituted quinazolinones | |
| JP6508544B2 (ja) | 腫瘍を治療するための薬用組成物 | |
| JP2015536986A (ja) | 併用療法 | |
| JP5903433B2 (ja) | 癌の治療に有用なｖｅｇｆｒ阻害剤およびｍｅｋ阻害剤の医薬的組み合わせ | |
| US20160375086A1 (en) | Combination | |
| AU2013329199A1 (en) | Combinations | |
| JP2016106092A (ja) | 組合せ | |
| EP2571358B1 (en) | Combination therapy for treating cancer | |
| CN113329749A (zh) | 用于治疗葡萄膜黑色素瘤的联合疗法 | |
| US20180214451A1 (en) | Combination | |
| EP2603078A1 (en) | Combination | |
| HK40061016A (en) | Combination therapy for the treatment of uveal melanoma | |
| JP2013526613A (ja) | 組合せ | |
| JP2015534987A (ja) | 組合せ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |